These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28395798)
21. Generation of a human induced pluripotent stem cell (iPSC) line carrying the Parkinson's disease linked LRRK2 variant S1647T. Ma D; Ng SH; Zeng L; Zhao Y; Tan EK Stem Cell Res; 2017 Jan; 18():54-56. PubMed ID: 28395805 [TBL] [Abstract][Full Text] [Related]
22. Reprogramming of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a R1628P variant in the LRRK2 gene. Ma D; Zhou W; Ng EY; Zeng L; Zhao Y; Tan EK Stem Cell Res; 2017 Jan; 18():45-47. PubMed ID: 28395802 [TBL] [Abstract][Full Text] [Related]
23. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700 [TBL] [Abstract][Full Text] [Related]
24. Generation of two induced pluripotent stem cell lines, GZHMCi009-A and GZHMCi010-A, derived from peripheral blood mononuclear cells of two SCA3 patients with 14/74 CAG repeats of the ATXN3 mutation. Yinghong Y; Qian L; Bing S; Yingjun X; Wenzhi H; Bangzhu C; Xiaofang S Stem Cell Res; 2022 May; 61():102782. PubMed ID: 35421843 [TBL] [Abstract][Full Text] [Related]
25. Development of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient carrying the N551K variant in LRRK2 gene. Ma D; Ng EY; Zeng L; Lim CY; Zhao Y; Tan EK Stem Cell Res; 2017 Jan; 18():51-53. PubMed ID: 28395804 [TBL] [Abstract][Full Text] [Related]
26. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
27. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650 [TBL] [Abstract][Full Text] [Related]
28. Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing. McIntosh CS; Aung-Htut MT; Fletcher S; Wilton SD Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683630 [TBL] [Abstract][Full Text] [Related]
29. ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3. Hernández-Carralero E; Quinet G; Freire R Expert Rev Mol Med; 2024 Sep; 26():e19. PubMed ID: 39320846 [TBL] [Abstract][Full Text] [Related]
30. Derivation of human induced pluripotent stem cell (iPSC) line with LRRK2 gene R1398H variant in Parkinson's disease. Ma D; Tio M; Ng SH; Li Zeng ; Lim CY; Zhao Y; Tan EK Stem Cell Res; 2017 Jan; 18():48-50. PubMed ID: 28395803 [TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells. He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635 [TBL] [Abstract][Full Text] [Related]
32. Derivation of spinocerebellar ataxia type 3 human embryonic stem cell line UMICHe001-A/UM134-1. Moore LR; Keller L; Paulson HL; Smith GD Stem Cell Res; 2022 Oct; 64():102873. PubMed ID: 35952620 [TBL] [Abstract][Full Text] [Related]
33. Generation of induced pluripotent stem cells (iPSCs) from a Bernard-Soulier syndrome patient carrying a W71R mutation in the GPIX gene. Lopez-Onieva L; Montes R; Lamolda M; Romero T; Ayllon V; Lozano ML; Vicente V; Rivera J; Ramos-Mejía V; Real PJ Stem Cell Res; 2016 May; 16(3):692-5. PubMed ID: 27346198 [TBL] [Abstract][Full Text] [Related]
34. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119 [TBL] [Abstract][Full Text] [Related]
35. Integration-free erythroblast-derived human induced pluripotent stem cells (iPSCs) from an individual with Ataxia-Telangiectasia (A-T). Bhatt N; Ghosh R; Roy S; Gao Y; Armanios M; Cheng L; Franco S Stem Cell Res; 2016 Sep; 17(2):205-207. PubMed ID: 27879207 [TBL] [Abstract][Full Text] [Related]
36. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3. Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445 [TBL] [Abstract][Full Text] [Related]
38. Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3/MJD. Wang C; Peng H; Li J; Ding D; Chen Z; Long Z; Peng Y; Zhou X; Ye W; Li K; Xu Q; Ai S; Song C; Weng L; Qiu R; Xia K; Tang B; Jiang H Neurobiol Aging; 2017 May; 53():192.e5-192.e10. PubMed ID: 28094059 [TBL] [Abstract][Full Text] [Related]
39. Development of human induced pluripotent stem cell (iPSC) line from a 60year old female patient with multiple schwannoma. Zhang S; Lv Z; Liu Y; Li Q; Gong W; Liu L; Wu H Stem Cell Res; 2017 Mar; 19():31-33. PubMed ID: 28413001 [TBL] [Abstract][Full Text] [Related]
40. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]